Life Science Partner recruits former CEO of AdipoGenix, Inc.
Life Science Partner announces the recruitment of Ed Cannon, an entrepreneurial pharmaceutical executive, to AerovectRx Corporation. AerovectRx is an early-stage aerosol therapeutic development company capitalizing upon its unique AeroCell™ disposable drug cartridge to improve patient compliance, eliminate multi-user cross contamination, and deliver a wide variety of vaccine and therapies. Licensed from the Centers for Disease Control, the delivery platform has the potential to improve vaccines, pulmonary drugs, and lung-delivered therapeutics for systemic diseases.
Cannon was the founder and CEO of AdipoGenix, Inc., an early stage biopharmaceutical company utilizing a novel drug discovery technology to isolate fat precursor cells and identify small molecule drug candidates that treat obesity and its co-morbidities. He was responsible for building a management and scientific team, creating strategy around the technology platform, and raising capital for the company. Earlier, Cannon was the founding CEO of Elixir Pharmaceuticals, where he successfully led the team through Series A and B funding and three major discovery programs, each with a lead series of compounds. In addition, Cannon was co-founder of Dyax Corporation where he was president of the therapeutics and diagnostics division.
“Ed is the consummate start-up biotech executive who understands the complexity of drug discovery and development, while executing on fundraising and business development activities,” noted Tom Callaway, MD, founder and president of Life Science Partner. “Working with founder Matthew Kim, Cannon will move the company’s platform to create new aerosol therapeutics through partnerships and the company’s own molecules.”
Cannon will build a start-up team overseeing research and product development, clinical and regulatory, operations and sales and marketing.
Cannon received a Bachelor of Science degree, a Masters in Statistics and Computer Sciences and his Ph.D. in Biochemistry from the University of Georgia. He completed his postdoctoral training in Molecular Immunology at Harvard Medical School and Massachusetts General Hospital in Boston.